<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02133911</url>
  </required_header>
  <id_info>
    <org_study_id>AHFTX-UMCLJ-1</org_study_id>
    <nct_id>NCT02133911</nct_id>
  </id_info>
  <brief_title>A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy</brief_title>
  <acronym>RAMP-DCM</acronym>
  <official_title>Effects of Ranolazine on Myocardial Perfusion in Patients With Dilated Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent data suggest that areas of fibrosis and hibernating myocardium develop in patients&#xD;
      with non ischemic dilated cardiomyopathy. Ranolazine is a new drug, developed to releave&#xD;
      symptoms of angina in patients with stable coronary disease that is not suitable for surgical&#xD;
      or percutaneous revascularization. It has been shown that in patients with stable coronary&#xD;
      disease Ranolazine improves myocardial perfusion as shown with myocardial nuclear imaging.&#xD;
      The aim of this trial is to evaluate effects of ranolazine on myocardial perfusion in&#xD;
      patients with dilated cardiomyopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent data suggest that areas of fibrosis and hibernating myocardium develop in patients&#xD;
      with non ischemic dilated cardiomyopathy. Ranolazine is a new drug, developed to releave&#xD;
      symptoms of angina in patients with stable coronary disease that is not suitable for surgical&#xD;
      or percutaneous revascularization. The main mechanism of action of Ranolazine is the&#xD;
      inhibition of late I(Na) thus decreasing the Ca++ load in the cardiomyocites. Consequently&#xD;
      oxygen consumption also decreases. It has also been shown that in patients with stable&#xD;
      coronary disease Ranolazine improves myocardial perfusion as shown with myocardial nuclear&#xD;
      imaging. The aim of this trial is to evaluate effects of ranolazine on myocardial perfusion&#xD;
      in patients with dilated cardiomyopathy.&#xD;
&#xD;
      Primary end-point: To determine wheather Ranolazine improves perfusion of the myocardium in&#xD;
      patients with non-ischemic dilated cardiomyopathy.&#xD;
&#xD;
      Secondary end-points: To determine wheather Ranolazine improves patients' NYHA functional&#xD;
      class, excercise capacity, LV systolic and diastolic function and weather ranolazine affects&#xD;
      supraventricular and ventricular arrhythmia occurance/frequency.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1, 2014</start_date>
  <completion_date type="Actual">April 2, 2016</completion_date>
  <primary_completion_date type="Actual">December 15, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial perfusion</measure>
    <time_frame>6 months</time_frame>
    <description>To determine wheather Ranolazine improves perfusion of the myocardium in patients with non-ischemic dilated cardiomyopathy assesed by myocardial nuclear imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Excercise capacity</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>To determine wheather Ranolazine improves patients' excercise capacity, assesed by 6' walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular systolic and diastolic function</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>To determine wheather Ranolazine improves patients' LV systolic and diastolic function, assesed by LVEF, TDI, LV longitudinal strain and strain rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supraventricular and ventricular arrhythmias</measure>
    <time_frame>6 months</time_frame>
    <description>To determine wheather Ranolazine affects the occurence of supraventricular and ventricular arrhythmia occurance/frequency using 24 holter monitor.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial dose is 375 mg bid. After 2 - 4 weeks the dose is increased to 500 mg bid and after another 2-4 weeks to 750 mg bid. In case of side effects the dose of the drug is to be decreased to the highest dose that the patient is still able to tolerate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  established diagnosis of non-ischemic dilated cardiomyopathy&#xD;
&#xD;
          -  EF &lt; 35%&#xD;
&#xD;
          -  NYHA f.c. II - IV&#xD;
&#xD;
          -  Optimal medical management &gt; 6 months&#xD;
&#xD;
          -  Age &lt; 75 years and &gt; 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known hypersensitivity to the medication&#xD;
&#xD;
          -  age &gt; 75 years or &lt; 18 years&#xD;
&#xD;
          -  EF &gt; 35%&#xD;
&#xD;
          -  renal insufficiency (GF &lt; 30)&#xD;
&#xD;
          -  liver dysfunction (liver tests &gt; 3x the upper normal limit))&#xD;
&#xD;
          -  LQT syndrome&#xD;
&#xD;
          -  drugs that affect CYP3A4 metabolism (azoles, macrolides, calcineurin inhibitors etc.)&#xD;
&#xD;
          -  dementia&#xD;
&#xD;
          -  active hemathological or malignant disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregor Poglajen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advanced Heart Failure and Transplantation Programme, University Medical Center Ljubljana, Slovenia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bojan Vrtovec, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Advanced Heart Failure and Transplantation Programme, University Medical Center Ljubljana, Slovenia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Heart Failure and Transplantation Programme, University Medical Center Ljubljana, Slovenia</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 6, 2014</study_first_submitted>
  <study_first_submitted_qc>May 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2014</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Gregor Poglajen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

